Seek Returns logo

RGC vs. WAT: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at RGC and WAT, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolRGCWAT
Company NameRegencell Bioscience Holdings LimitedWaters Corporation
CountryHong KongUnited States
GICS SectorHealth CareHealth Care
GICS IndustryPharmaceuticalsLife Sciences Tools & Services
Market Capitalization6.07 billion USD17.79 billion USD
ExchangeNasdaqCMNYSE
Listing DateJuly 16, 2021November 17, 1995
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of RGC and WAT by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

RGC vs. WAT: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolRGCWAT
5-Day Price Return-3.94%0.41%
13-Week Price Return17.22%-14.21%
26-Week Price Return12,700.00%-20.91%
52-Week Price Return5,995.24%-11.05%
Month-to-Date Return-3.03%3.53%
Year-to-Date Return9,746.15%-19.42%
10-Day Avg. Volume0.19M0.59M
3-Month Avg. Volume2.18M0.69M
3-Month Volatility642.38%38.80%
Beta2.331.06

Profitability

Return on Equity (TTM)

RGC

-54.75%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

WAT

35.02%

Life Sciences Tools & Services Industry

Max
19.96%
Q3
11.55%
Median
6.22%
Q1
3.86%
Min
-6.95%

WAT’s Return on Equity of 35.02% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

RGC vs. WAT: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Net Profit Margin (TTM)

RGC

--

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

Net Profit Margin data for RGC is currently unavailable.

WAT

21.71%

Life Sciences Tools & Services Industry

Max
27.28%
Q3
16.17%
Median
7.24%
Q1
3.00%
Min
-3.05%

A Net Profit Margin of 21.71% places WAT in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.

RGC vs. WAT: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Operating Profit Margin (TTM)

RGC

--

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

Operating Profit Margin data for RGC is currently unavailable.

WAT

27.69%

Life Sciences Tools & Services Industry

Max
33.15%
Q3
19.34%
Median
13.02%
Q1
8.05%
Min
-4.38%

An Operating Profit Margin of 27.69% places WAT in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RGC vs. WAT: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Profitability at a Glance

SymbolRGCWAT
Return on Equity (TTM)-54.75%35.02%
Return on Assets (TTM)-51.38%14.40%
Net Profit Margin (TTM)--21.71%
Operating Profit Margin (TTM)--27.69%
Gross Profit Margin (TTM)--59.02%

Financial Strength

Current Ratio (MRQ)

RGC

42.68

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

WAT

1.75

Life Sciences Tools & Services Industry

Max
4.76
Q3
2.77
Median
1.85
Q1
1.40
Min
0.43

WAT’s Current Ratio of 1.75 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.

RGC vs. WAT: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

RGC

0.00

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

WAT

0.67

Life Sciences Tools & Services Industry

Max
1.75
Q3
0.83
Median
0.41
Q1
0.18
Min
0.00

WAT’s Debt-to-Equity Ratio of 0.67 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RGC vs. WAT: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Interest Coverage Ratio (TTM)

RGC

--

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

Interest Coverage Ratio data for RGC is currently unavailable.

WAT

11.29

Life Sciences Tools & Services Industry

Max
29.61
Q3
23.24
Median
6.07
Q1
2.18
Min
-14.08

WAT’s Interest Coverage Ratio of 11.29 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.

RGC vs. WAT: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Financial Strength at a Glance

SymbolRGCWAT
Current Ratio (MRQ)42.681.75
Quick Ratio (MRQ)41.891.22
Debt-to-Equity Ratio (MRQ)0.000.67
Interest Coverage Ratio (TTM)--11.29

Growth

Revenue Growth

RGC vs. WAT: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

RGC vs. WAT: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

WAT

0.00%

Life Sciences Tools & Services Industry

Max
1.80%
Q3
0.78%
Median
0.37%
Q1
0.00%
Min
0.00%

WAT currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

RGC vs. WAT: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Dividend Payout Ratio (TTM)

RGC

0.00%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

WAT

0.00%

Life Sciences Tools & Services Industry

Max
156.00%
Q3
65.73%
Median
23.81%
Q1
0.00%
Min
0.00%

WAT has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

RGC vs. WAT: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Dividend at a Glance

SymbolRGCWAT
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

RGC

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for RGC is currently unavailable.

WAT

26.76

Life Sciences Tools & Services Industry

Max
117.96
Q3
65.59
Median
37.26
Q1
27.51
Min
1.73

In the lower quartile for the Life Sciences Tools & Services industry, WAT’s P/E Ratio of 26.76 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

RGC vs. WAT: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

RGC

--

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

P/S Ratio data for RGC is currently unavailable.

WAT

5.81

Life Sciences Tools & Services Industry

Max
12.46
Q3
6.70
Median
4.24
Q1
2.68
Min
0.73

WAT’s P/S Ratio of 5.81 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RGC vs. WAT: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

RGC

9.57

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

WAT

9.62

Life Sciences Tools & Services Industry

Max
7.99
Q3
4.69
Median
3.30
Q1
1.88
Min
1.02

At 9.62, WAT’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

RGC vs. WAT: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Life Sciences Tools & Services industry benchmarks.

Valuation at a Glance

SymbolRGCWAT
Price-to-Earnings Ratio (TTM)--26.76
Price-to-Sales Ratio (TTM)--5.81
Price-to-Book Ratio (MRQ)9.579.62
Price-to-Free Cash Flow Ratio (TTM)--28.57